Major depressive disorder (MDD) affects more than 350 million people world-wide. Large heterogeneities in patient symptoms has led to several different treatment courses. Although treatments, such as SSRIs, are generally effective, a large portion of patients (~30%) do not achieve remission. The ability to predict which treatment option will yield the best outcome would be of great use to clinicians and patients. The GABAergic system is implicated in MDD and affected by SSRIs. In this study GABA concentrations were measured with MEGA-PRESS MRS in MDD patients before and after treatment with a SSRI to determine predictive ability and treatment changes.